Pharming Group N.V. announced today that it has concluded its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA).

Pharming Group N.V. today announced that since the release of its 2017 Half Year Report on 27 July 2017, it has issued 12,053,268 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2017.

Pharming Group N.V. today announced The Lancet has published data from a Phase II, double-blind, placebo-controlled, randomized clinical trial (NCT02247739) evaluating the efficacy and safety of RUCONEST® (C1 esterase inhibitor [recombinant]) for the prevention of hereditary angioedema (HAE) attacks.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming Group N.V. today announced that the supervisory board and the management board have jointly decided to withdraw the agenda items related to the Amendment of Pharming’s Articles of Association from the agenda of the AGM scheduled for Wednesday, 24 May 2017 at 14:00 hours.

Pharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2017.

On May the 16th Hereditary Angioedema (HAE) patient organizationsfrom around the world, led by HAEi ( The international HAE patient organisation) come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition.

Pharming Group N.V. announces that it has completed a new US$100 million finance agreement with Orbimed Advisors.

Pharming Group N.V. presents its (unaudited) financial report for the full year ended 31 December 2016.